DP2: Notice of stock status

On April 01, 2024, HNX announces the status of Central Pharmaceutical Joint Stock Company No2’s shares (stock code: DP2) as follows: DP2 shares are under continued trading restriction due to the reasons that the audit organization have expressed disclaimer opinion on the Annual Financial Statements 2023 as prescribed at points c, Section 1, Article 34 of the Regulations attached to Decision No.34/QD-HDTV dated 16/11/2022 of the Vietnam Exchange.

HNX

>   GGG: Decision on continued trading restriction and Notice of stock status (02/04/2024)

>   SJM: Board Decision (02/04/2024)

>   SBB: Board Decision (02/04/2024)

>   DSC: Annual General Mandate 2024 (02/04/2024)

>   DDM: Explanation on maintaining transaction restrictions (02/04/2024)

>   DM7: Board Resolution (02/04/2024)

>   BAB: 10/04/2024, first trading date of additional shares (02/04/2024)

>   LMC: Board Resolution (02/04/2024)

>   HSP: Annual General Mandate 2024 (02/04/2024)

>   GER: Annual General Mandate 2024 (02/04/2024)